title: Evaluation of fructose 1,6 diphosphate for salvage of ischemic gracilis flaps in rats.
abstract: Fructose 1, 6 diphosphate (FDP), a metabolic intermediate, provides an alternative mechanism to circumvent the rate-limiting step in the Kreb's cycle. This agent has been observed to prevent the effects of ischemia on heart tissue and kidney function and the effects of endotoxic shock. It has been shown conclusively to minimize the adverse effects of ischemia-reperfusion injury in experimental pedicled skin flaps in animals. The present study was done to evaluate the effect of intra-arterial administration of FDP on salvage of ischemic microvascular transfer of gracilis muscle flaps in rats, with the premise that it might prolong the ischemia time of muscle flaps at room temperature, thus increasing chances of flap survival. Irrigation with FDP did not change the quantitative survival of the flaps, but there was qualitative improvement on histologic evaluation and DNA analysis. Decreased inflammatory damage and DNA fragmentation were seen at the 2.5-hr period. Histologic staining for mitochondrial oxygenation in gracilis muscle also showed increased uptake in the FDP-treated group vs. control at the 2.5-hr ischemia period. Further experiments with different modes of FDP administration should be carried out to identify more effective means of amelioration of flap ischemia.
authors.affiliation: Division Of Plastic Surgery, Department of Surgery, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA.
authors.forename: Vipul
authors.initials: V
authors.lastname: Sud
authors.forename: Sheila G
authors.initials: SG
authors.lastname: Lindley
authors.forename: Olga
authors.initials: O
authors.lastname: McDaniel
authors.forename: Alan E
authors.initials: AE
authors.lastname: Freeland
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Wanda
authors.initials: W
authors.lastname: Dorsett-Martin
authors.forename: Steven A
authors.initials: SA
authors.lastname: Bigler
authors.forename: William
authors.initials: W
authors.lastname: Lineaweaver
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005635:Fructosediphosphates / Q000494:pharmacology / Q000627:therapeutic use*; D006085:Graft Survival / Q000187:drug effects; D007511:Ischemia / Q000188:drug therapy*; D008297:Male; D023421:Models, Animal; D018482:Muscle, Skeletal / Q000098:blood supply; D051381:Rats; D017207:Rats, Sprague-Dawley; D013524:Surgical Flaps / Q000098:blood supply*
chemical_list: D002317:Cardiovascular Agents; D005635:Fructosediphosphates; C029063:fructose-1,6-diphosphate